Janne Kærn
Position: Senior consultant, MD, PhD
Phone: +47 22 93 44 46
Email:

Download CV (in Word format)

 

Author network for Janne Kærn by COREMINE medical


Publications 2016

Sorio R, Roemer-Becuwe C, Hilpert F, Gibbs E, García Y, Kaern J, Huizing M, Witteveen P, Zagouri F, Coeffic D, Lück HJ, González-Martín A, Kristensen G, Levaché CB, Lee CK, Gebski V, Pujade-Lauraine E, AURELIA Investigators (2016)
Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial
Gynecol Oncol, 144 (1), 65-71
PubMed 27871723

Szczesny W, Vistad I, Kaern J, Nakling J, Tropé C, Paulsen T (2016)
Impact of hospital type and treatment on long-term survival among patients with FIGO Stage IIIC epithelial ovarian cancer: follow-up through two recurrences and three treatment lines in search for predictors for survival
Eur J Gynaecol Oncol, 37 (3), 305-11
PubMed 27352555

Publications 2014

Davidson B, Nymoen DA, Elgaaen BV, Staff AC, Tropé CG, Kærn J, Reich R, Falkenthal TE (2014)
BUB1 mRNA is significantly co-expressed with AURKA and AURKB mRNA in advanced-stage ovarian serous carcinoma
Virchows Arch, 464 (6), 701-7
PubMed 24756216

Solheim O, Tropé CG, Rokkones E, Kærn J, Paulsen T, Salvesen HB, Hagen B, Vereide AB, Fosså SD (2014)
Fertility and gonadal function after adjuvant therapy in women diagnosed with a malignant ovarian germ cell tumor (MOGCT) during the "cisplatin era"
Gynecol Oncol, 136 (2), 224-9
PubMed 25511159

Tuft Stavnes H, Nymoen DA, Hetland Falkenthal TE, Kærn J, Tropé CG, Davidson B (2014)
APOA1 mRNA expression in ovarian serous carcinoma effusions is a marker of longer survival
Am J Clin Pathol, 142 (1), 51-7
PubMed 24926085

Publications 2013

Davidson B, Smith Y, Nesland JM, Kærn J, Reich R, Tropè CG (2013)
Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion
Hum Pathol, 44 (11), 2449-60
PubMed 24011953

Sioud M, Saebøe-Larssen S, Hetland TE, Kaern J, Mobergslien A, Kvalheim G (2013)
Silencing of indoleamine 2,3-dioxygenase enhances dendritic cell immunogenicity and antitumour immunity in cancer patients
Int J Oncol, 43 (1), 280-8
PubMed 23620105

Solheim O, Kærn J, Tropé CG, Rokkones E, Dahl AA, Nesland JM, Fosså SD (2013)
Malignant ovarian germ cell tumors: presentation, survival and second cancer in a population based Norwegian cohort (1953-2009)
Gynecol Oncol, 131 (2), 330-5
PubMed 24001518

Stavnes HT, Holth A, Don T, Kærn J, Vaksman O, Reich R, Trope' CG, Davidson B (2013)
HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival
Gynecol Oncol, 129 (2), 358-63
PubMed 23438671

Vettukattil R, Hetland TE, Flørenes VA, Kærn J, Davidson B, Bathen TF (2013)
Proton magnetic resonance metabolomic characterization of ovarian serous carcinoma effusions: chemotherapy-related effects and comparison with malignant mesothelioma and breast carcinoma
Hum Pathol, 44 (9), 1859-66
PubMed 23656974

Publications 2012

Hetland TE, Holth A, Kærn J, Flørenes VA, Tropé CG, Davidson B (2012)
HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases
Virchows Arch, 460 (5), 505-13
PubMed 22476403

Hetland TE, Kærn J, Skrede M, Sandstad B, Tropé C, Davidson B, Flørenes VA (2012)
Predicting platinum resistance in primary advanced ovarian cancer patients with an in vitro resistance index
Cancer Chemother Pharmacol, 69 (5), 1307-14
PubMed 22302409

Hetland TE, Nymoen DA, Emilsen E, Kærn J, Tropé CG, Flørenes VA, Davidson B (2012)
MGST1 expression in serous ovarian carcinoma differs at various anatomic sites, but is unrelated to chemoresistance or survival
Gynecol Oncol, 126 (3), 460-5
PubMed 22652154

Hetland TE, Nymoen DA, Holth A, Brusegard K, Flørenes VA, Kærn J, Tropé CG, Davidson B (2012)
Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance
Hum Pathol, 44 (5), 777-85
PubMed 23114921

Lindemann K, Christensen RD, Vergote I, Stuart G, Izquierdo MA, Kærn J, Havsteen H, Eisenhauer E, Ridderheim M, Lopez AB, Hirte H, Aavall-Lundquvist E, Vrdoljak E, Green J, Kristensen GB (2012)
First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)--a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG
Ann Oncol, 23 (10), 2613-9
PubMed 22539562

Tropé CG, Kaern J, Davidson B (2012)
Borderline ovarian tumours
Best Pract Res Clin Obstet Gynaecol, 26 (3), 325-36
PubMed 22321906

Wagner U, Marth C, Largillier R, Kaern J, Brown C, Heywood M, Bonaventura T, Vergote I, Piccirillo MC, Fossati R, Gebski V, Lauraine EP (2012)
Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients
Br J Cancer, 107 (4), 588-91
PubMed 22836511

Publications 2011

Bock AJ, Nymoen DA, Brenne K, Kærn J, Davidson B (2011)
SCARA3 mRNA is overexpressed in ovarian carcinoma compared with breast carcinoma effusions
Hum Pathol, 43 (5), 669-74
PubMed 21855113

Bock AJ, Tuft Stavnes H, Kærn J, Berner A, Staff AC, Davidson B (2011)
Endoglin (CD105) expression in ovarian serous carcinoma effusions is related to chemotherapy status
Tumour Biol, 32 (3), 589-96
PubMed 21350924

Hetland TE, Hellesylt E, Flørenes VA, Tropé C, Davidson B, Kærn J (2011)
Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance
Hum Pathol, 42 (7), 1019-26
PubMed 21315408

Paulsen T, Kærn J, Tropé C (2011)
Improved 5-year disease-free survival for FIGO stage I epithelial ovarian cancer patients without tumor rupture during surgery
Gynecol Oncol, 122 (1), 83-8
PubMed 21435701

Vaksman O, Stavnes HT, Kaern J, Trope CG, Davidson B, Reich R (2011)
miRNA profiling along tumour progression in ovarian carcinoma
J Cell Mol Med, 15 (7), 1593-602
PubMed 20716115

Publications 2009

Tropé C, Davidson B, Paulsen T, Abeler VM, Kaern J (2009)
Diagnosis and treatment of borderline ovarian neoplasms "the state of the art"
Eur J Gynaecol Oncol, 30 (5), 471-82
PubMed 19899396

Publications 2007

Hoei-Hansen CE, Kraggerud SM, Abeler VM, Kaern J, Rajpert-De Meyts E, Lothe RA (2007)
Ovarian dysgerminomas are characterised by frequent KIT mutations and abundant expression of pluripotency markers
Mol Cancer, 6, 12
PubMed 17274819

Paulsen T, Ree AH, Kaern J, Kjaerheim K, Bassarova A, Berner A, Haldorsen T, Tropé C, Nesland JM (2007)
Expression of matrix metalloproteinase-2 in serous borderline ovarian tumors is associated with noninvasive implant formation
Eur J Gynaecol Oncol, 28 (5), 356-63
PubMed 17966213

Tropé C, Kaern J (2007)
Adjuvant chemotherapy for early-stage ovarian cancer: review of the literature
J Clin Oncol, 25 (20), 2909-20
PubMed 17617522

Publications 2006

Aghmesheh M, Suo Z, Friedlander M, Nesland JM, Kaern J, Stewart M, Kconfab, Dorum A, Tucker KM, Buckley MF (2006)
Chromosome 2q24.2 is lost in sporadic but not in BRCA1-associated ovarian carcinomas
Pathology, 38 (2), 145-51
PubMed 16680901

Paulsen T, Kaern J, Kjaerheim K, Haldorsen T, Tropé C (2006)
Influence of interval between primary surgery and chemotherapy on short-term survival of patients with advanced ovarian, tubal or peritoneal cancer
Gynecol Oncol, 102 (3), 447-52
PubMed 16516277

Paulsen T, Kjaerheim K, Kaern J, Tretli S, Tropé C (2006)
Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals
Int J Gynecol Cancer, 16 Suppl 1, 11-7
PubMed 16515561

Tropé C, Kaern J (2006)
Primary surgery for ovarian cancer
Eur J Surg Oncol, 32 (8), 844-52
PubMed 16677797

Publications 2005

Kaern J, Aghmesheh M, Nesland JM, Danielsen HE, Sandstad B, Friedlander M, Tropé C (2005)
Prognostic factors in ovarian carcinoma stage III patients. Can biomarkers improve the prediction of short- and long-term survivors?
Int J Gynecol Cancer, 15 (6), 1014-22
PubMed 16343177

Paulsen T, Kaern J, Kjaerheim K, Tropé C, Tretli S (2005)
Symptoms and referral of women with epithelial ovarian tumors
Int J Gynaecol Obstet, 88 (1), 31-7
PubMed 15617702

Reich R, Vintman L, Nielsen S, Kaern J, Bedrossian C, Berner A, Davidson B (2005)
Differential expression of the 67 kilodalton laminin receptor in epithelioid malignant mesothelioma and carcinomas that spread to serosal cavities
Diagn Cytopathol, 33 (5), 332-7
PubMed 16240397

Ødegaard E, Staff AC, Kaern J, Flørenes VA, Kopolovic J, Tropé CG, Abeler VM, Reich R, Davidson B (2005)
The AP-2gamma transcription factor is upregulated in advanced-stage ovarian carcinoma
Gynecol Oncol, 100 (3), 462-8
PubMed 16216317

Publications 2004

Aghmesheh M, Nesland JM, Kaern J, Dorum A, Edwards L, Byth K, Friedlander M, Jackson P, Tucker KM, Russell PJ (2004)
No differences in p53 mutation frequencies between BRCA1-associated and sporadic ovarian cancers
Gynecol Oncol, 95 (3), 430-6
PubMed 15581943

Kildal W, Kaern J, Kraggerud SM, Abeler VM, Sudbø J, Tropè CG, Lothe RA, Danielsen HE (2004)
Evaluation of genomic changes in a large series of malignant ovarian germ cell tumors--relation to clinicopathologic variables
Cancer Genet Cytogenet, 155 (1), 25-32
PubMed 15527899

Xi Z, Kaern J, Davidson B, Klokk TI, Risberg B, Tropé C, Saatcioglu F (2004)
Kallikrein 4 is associated with paclitaxel resistance in ovarian cancer
Gynecol Oncol, 94 (1), 80-5
PubMed 15262123

Publications 2003

Kristensen GB, Kildal W, Abeler VM, Kaern J, Vergote I, Tropé CG, Danielsen HE (2003)
Large-scale genomic instability predicts long-term outcome for women with invasive stage I ovarian cancer
Ann Oncol, 14 (10), 1494-500
PubMed 14504048

Kristensen GB, Vergote I, Stuart G, Del Campo JM, Kaern J, Lopez AB, Eisenhauer E, Aavall-Lundquist E, Ridderheim M, Havsteen H, Mirza MR, Scheistroen M, Vrdoljak E (2003)
First-line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin
Int J Gynecol Cancer, 13 Suppl 2, 172-7
PubMed 14656276

Piccart MJ, Bertelsen K, Stuart G, Cassidy J, Mangioni C, Simonsen E, James K, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson R, Swenerton K, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lidvall B, Bacon M, Birt A, Andersen J, Zee B et al. (2003)
Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer
Int J Gynecol Cancer, 13 Suppl 2, 144-8
PubMed 14656271

Tropé C, Kaern J, Saeter G, Gore M (2003)
[Paclitaxel should be included in standard therapy of ovarian carcinoma]
Tidsskr Nor Laegeforen, 123 (21), 3083-4
PubMed 14618184

Publications 2002

Bjørge T, Abeler VM, Sundfør K, Tropé CG, Kaern J (2002)
Gestational trophoblastic tumors in Norway, 1968-1997: patient characteristics, treatment, and prognosis
Gynecol Oncol, 87 (1), 71-6
PubMed 12468345

Kaern J, Baekelandt M, Tropé CG (2002)
A phase II study of weekly paclitaxel in platinum and paclitaxel-resistant ovarian cancer patients
Eur J Gynaecol Oncol, 23 (5), 383-9
PubMed 12440808

Marth C, Kisic J, Kaern J, Tropé C, Fodstad Ø (2002)
Circulating tumor cells in the peripheral blood and bone marrow of patients with ovarian carcinoma do not predict prognosis
Cancer, 94 (3), 707-12
PubMed 11857303

Monclair T, Abeler VM, Kaern J, Walaas L, Zeller B, Hilstrøm C (2002)
Placental site trophoblastic tumor (PSTT) in mother and child: first report of PSTT in infancy
Med Pediatr Oncol, 38 (3), 187-91; discussion 192
PubMed 11836719

Publications 2001

Paulsen T, Kjaerheim K, Kaern J, Norstein J, Onsrud M (2001)
[Examination, treatment and follow-up of ovarian cancer in Norway]
Tidsskr Nor Laegeforen, 121 (23), 2696-700
PubMed 11699376

Tropé C, Kristensen G, Kisic J, Kaern J (2001)
Long-term results from a phase II study of paclitaxel combined with doxorubicin in recurrent platinum refractory ovarian cancer
Eur J Gynaecol Oncol, 22 (3), 223-7
PubMed 11501778

Vergote I, De Brabanter J, Fyles A, Bertelsen K, Einhorn N, Sevelda P, Gore ME, Kaern J, Verrelst H, Sjövall K, Timmerman D, Vandewalle J, Van Gramberen M, Tropé CG (2001)
Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma
Lancet, 357 (9251), 176-82
PubMed 11213094

Publications 2000

Kraggerud SM, Szymanska J, Abeler VM, Kaern J, Eknaes M, Heim S, Teixeira MR, Tropé CG, Peltomäki P, Lothe RA (2000)
DNA copy number changes in malignant ovarian germ cell tumors
Cancer Res, 60 (11), 3025-30
PubMed 10850452

Paulsen T, Marth C, Kaern J, Nustad K, Kristensen GB, Tropé C (2000)
Effects of paclitaxel on CA-125 serum levels in ovarian cancer patients
Gynecol Oncol, 76 (3), 326-30
PubMed 10684705

Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson RJ, Swenerton KD, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen JE, Zee B et al. (2000)
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results
J Natl Cancer Inst, 92 (9), 699-708
PubMed 10793106

Tropé C, Kaern J, Hogberg T, Abeler V, Hagen B, Kristensen G, Onsrud M, Pettersen E, Rosenberg P, Sandvei R, Sundfor K, Vergote I (2000)
Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument
Ann Oncol, 11 (3), 281-8
PubMed 10811493

Tropé C, Marth C, Kaern J (2000)
Tamoxifen in the treatment of recurrent ovarian carcinoma
Eur J Cancer, 36 Suppl 4, S59-61
PubMed 11056321

Tropé CG, Abeler V, Baekelandt M, Kaern J (2000)
[DNA ploidy in epithelial ovarian cancer--an independent prognostic factor]
Tidsskr Nor Laegeforen, 120 (1), 43-9
PubMed 10815478

Tropé CG, Baekelandt M, Bjørge T, Abeler V, Kaern J (2000)
[Borderline tumors of the ovary]
Tidsskr Nor Laegeforen, 120 (23), 2764-70
PubMed 11107921

Publications 1999

Hanigan MH, Frierson HF, Abeler VM, Kaern J, Taylor PT (1999)
Human germ cell tumours: expression of gamma-glutamyl transpeptidase and sensitivity to cisplatin
Br J Cancer, 81 (1), 75-9
PubMed 10487615

Marth C, Sundfor K, Kaern J, Tropé C (1999)
Long-term follow-up of neoadjuvant cisplatin and 5-fluorouracil chemotherapy in bulky squamous cell carcinoma of the cervix
Acta Oncol, 38 (4), 517-20
PubMed 10418721

Publications 1998

Paulsen T, Kaern J, Tropé C (1998)
Carboplatin/5-fluorouracil treatment of recurrent cervical carcinoma: a phase II study with long-term follow-up
Eur J Gynaecol Oncol, 19 (6), 524-8
PubMed 10215433

Smith-Sørensen B, Kaern J, Holm R, Dørum A, Tropé C, Børresen-Dale AL (1998)
Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status
Br J Cancer, 78 (3), 375-81
PubMed 9703286

Tropé C, Hogberg T, Kaern J, Bertelsen K, Bjorkholm E, Boman K, Himmelmann A, Horvath G, Jacobsen A, Kuoppola T, Vartianen J, Lund B, Onsrud M, Puistola U, Salmi T, Scheistroen M, Sandvei R, Simonsen E, Sorbe B, Tholander B, Westberg R (1998)
Long-term results from a phase II study of single agent paclitaxel (Taxol) in previously platinum treated patients with advanced ovarian cancer: the Nordic experience
Ann Oncol, 9 (12), 1301-7
PubMed 9932160

Tropé C, Kaern J (1998)
Management of borderline tumors of the ovary: state of the art
Semin Oncol, 25 (3), 372-80
PubMed 9633850

Publications 1997

Marth C, Sorheim N, Kaern J, Trope C (1997)
Tamoxifen in the treatment of recurrent ovarian carcinoma
Int. J. Gynecol. Cancer, 7 (4), 256-261

Marth C, Widschwendter M, Kaern J, Jørgensen NP, Windbichler G, Zeimet AG, Tropé C, Daxenbichler G (1997)
Cisplatin resistance is associated with reduced interferon-gamma-sensitivity and increased HER-2 expression in cultured ovarian carcinoma cells
Br J Cancer, 76 (10), 1328-32
PubMed 9374379

Marth C, Zeimet AG, Widschwendter M, Ludescher C, Kaern J, Tropé C, Gastl G, Daxenbichler G, Dapunt O (1997)
Paclitaxel- and docetaxel-dependent activation of CA-125 expression in human ovarian carcinoma cells
Cancer Res, 57 (17), 3818-22
PubMed 9288793

Scheistrøen M, Tropé C, Kaern J, Pettersen EO, Alfsen GC, Nesland JM (1997)
DNA ploidy and expression of p53 and C-erbB-2 in extramammary Paget's disease of the vulva
Gynecol Oncol, 64 (1), 88-92
PubMed 8995553

Tropé C, Kaern J, Kristensen G, Rosenberg P, Sorbe B (1997)
Paclitaxel in untreated FIGO stage III suboptimally resected ovarian cancer
Ann Oncol, 8 (8), 803-6
PubMed 9332691

Publications 1996

Kaern J, Tropé C, Sundfoer K, Kristensen GB (1996)
Cisplatin/5-fluorouracil treatment of recurrent cervical carcinoma: a phase II study with long-term follow-up
Gynecol Oncol, 60 (3), 387-92
PubMed 8774643

Kristensen GB, Karlsen F, Jenkins A, Kaern J, Abeler VM, Tropé CG (1996)
Human papilloma virus has no prognostic significance in cervical carcinoma
Eur J Cancer, 32A (8), 1349-53
PubMed 8869098

Nordal RR, Kristensen GB, Kaern J, Stenwig AE, Pettersen EO, Tropé CG (1996)
The prognostic significance of surgery, tumor size, malignancy grade, menopausal status, and DNA ploidy in endometrial stromal sarcoma
Gynecol Oncol, 62 (2), 254-9
PubMed 8751558

Scheistrøen M, Tropé C, Kaern J, Abeler VM, Pettersen EO, Kristensen GB (1996)
Malignant melanoma of the vulva FIGO stage I: Evaluation of prognostic factors in 43 patients with emphasis on DNA ploidy and surgical treatment
Gynecol Oncol, 61 (2), 253-8
PubMed 8626143

Trope C, Hansen LJ, Kaern J, Abeler V (1996)
State of art in endometrial carcinoma
4TH CONGRESS OF THE EUROPEAN SOCIETY FOR GYNAECOLOGICAL ENDOSCOPY: THE UTERUS THROUGHOUT THE WOMAN'S LIFE, 107-115

Tropé C, Kaern J (1996)
Prognosis and management of borderline tumours of the ovary
Curr Opin Obstet Gynecol, 8 (1), 12-6
PubMed 8777251

Publications 1995

Kristensen GB, Kaern J, Abeler VM, Hagmar B, Tropé CG, Pettersen EO (1995)
No prognostic impact of flow-cytometric measured DNA ploidy and S-phase fraction in cancer of the uterine cervix: a prospective study of 465 patients
Gynecol Oncol, 57 (1), 79-85
PubMed 7705705

Nordal RR, Kristensen GB, Kaern J, Stenwig AE, Pettersen EO, Tropé CG (1995)
The prognostic significance of stage, tumor size, cellular atypia and DNA ploidy in uterine leiomyosarcoma
Acta Oncol, 34 (6), 797-802
PubMed 7576748

Raju KS, King RJ, Kaern J, Sumner D, Abeler VM, Mandalaya S, Trope C (1995)
Influence of HSP27 and steroid receptor status on provera sensitivity, DNA-ploidy and survival of females with endometrial cancer
Int J Gynecol Cancer, 5 (2), 94-100
PubMed 11578461

Publications 1994

Kaern J, Tropé CG, Kristensen GB, Pettersen EO (1994)
Flow cytometric DNA ploidy and S-phase heterogeneity in advanced ovarian carcinoma
Cancer, 73 (7), 1870-7
PubMed 8137213

Kaern J, Tropé CG, Kristensen GB, Tveit KM, Pettersen EO (1994)
Evaluation of deoxyribonucleic acid ploidy and S-phase fraction as prognostic parameters in advanced epithelial ovarian carcinoma: a prospective study
Am J Obstet Gynecol, 170 (2), 479-87
PubMed 8116701

Kristiansen E, Jenkins A, Kristensen G, Ask E, Kaern J, Abeler V, Lindqvist BH, Tropé C, Kristiansen BE (1994)
Human papillomavirus infection in Norwegian women with cervical cancer
APMIS, 102 (2), 122-8
PubMed 8167008

Tropé C, Kaern J (1994)
DNA ploidy in epithelial ovarian cancer: a new independent prognostic factor?
Gynecol Oncol, 53 (1), 1-4
PubMed 8175006

Publications 1993

Berek JS, Martínez-Maza O, Hamilton T, Tropé C, Kaern J, Baak J, Rustin GJ (1993)
Molecular and biological factors in the pathogenesis of ovarian cancer
Ann Oncol, 4 Suppl 4, 3-16
PubMed 8312207

Helland A, Holm R, Kristensen G, Kaern J, Karlsen F, Trope C, Nesland JM, Børresen AL (1993)
Genetic alterations of the TP53 gene, p53 protein expression and HPV infection in primary cervical carcinomas
J Pathol, 171 (2), 105-14
PubMed 8283348

Kaern J, Tropé CG, Abeler VM (1993)
A retrospective study of 370 borderline tumors of the ovary treated at the Norwegian Radium Hospital from 1970 to 1982. A review of clinicopathologic features and treatment modalities
Cancer, 71 (5), 1810-20
PubMed 8383580

Kaern J, Tropé CG, Kristensen GB, Abeler VM, Pettersen EO (1993)
DNA ploidy; the most important prognostic factor in patients with borderline tumors of the ovary
Int J Gynecol Cancer, 3 (6), 349-358
PubMed 11578368

Makar AP, Kaern J, Kristensen GB, Vergote I, Børmer OP, Tropé CG (1993)
Evaluation of serum CA 125 level as a tumor marker in borderline tumors of the ovary
Int J Gynecol Cancer, 3 (5), 299-303
PubMed 11578361

Tropé C, Kaern J, Vergote IB, Kristensen G, Abeler V (1993)
Are borderline tumors of the ovary overtreated both surgically and systemically? A review of four prospective randomized trials including 253 patients with borderline tumors
Gynecol Oncol, 51 (2), 236-43
PubMed 8276300

Vergote IB, Kaern J, Abeler VM, Pettersen EO, De Vos LN, Tropé CG (1993)
Analysis of prognostic factors in stage I epithelial ovarian carcinoma: importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse
Am J Obstet Gynecol, 169 (1), 40-52
PubMed 8333474

Publications 1992

Ask E, Jenkins A, Kaern J, Trope C, Kristiansen BE (1992)
Comparison of HPV detection in parallel biopsies and cervical scrapes by PCR
APMIS, 100 (8), 752-6
PubMed 1325806

Børresen AL, Helland A, Nesland J, Holm R, Trope C, Kaern J (1992)
Papillomaviruses, p53, and cervical cancer
Lancet, 339 (8805), 1350-1
PubMed 1350005

Helland A, Børresen AL, Kaern J, Rønningen KS, Thorsby E (1992)
HLA antigens and cervical carcinoma
Nature, 356 (6364), 23
PubMed 1538776

Kaern J, Iversen T, Tropé C, Pettersen EO, Nesland JM (1992)
Flow cytometric DNA measurements in squamous cell carcinoma of the vulva: an important prognostic method
Int J Gynecol Cancer, 2 (4), 169-174
PubMed 11576255

Kaern J, Wetteland J, Tropé CG, Farrants GW, Juhng SW, Pettersen EO, Reith A, Danielsen HE (1992)
Comparison between flow cytometry and image cytometry in ploidy distribution assessments in gynecologic cancer
Cytometry, 13 (3), 314-21
PubMed 1576895

Makar AP, Kristensen GB, Kaern J, Børmer OP, Abeler VM, Tropé CG (1992)
Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis
Obstet Gynecol, 79 (6), 1002-10
PubMed 1579296

Ramm K, Vergote IB, Kaern J, Tropé CG (1992)
Bleomycin-ifosfamide-cis-platinum (BIP) in pelvic recurrence of previously irradiated cervical carcinoma: a second look
Gynecol Oncol, 46 (2), 203-7
PubMed 1379961

Tropé C, Makar A, Kaern J (1992)
DNA flow cytometry as a new prognostic factor in ovarian malignancies. A review
Acta Obstet Gynecol Scand Suppl, 155, 95-7
PubMed 1502897

TROPE C, MAKAR A, KAERN J (1992)
DNA FLOW-CYTOMETRY AS A NEW PROGNOSTIC FACTOR IN OVARIAN MALIGNANCIES - A REVIEW
Acta Obstet. Gynecol. Scand., 71 155, 95-97

Publications 1991

Lien HH, Blomlie V, Tropé C, Kaern J, Abeler VM (1991)
Cancer of the endometrium: value of MR imaging in determining depth of invasion into the myometrium
AJR Am J Roentgenol, 157 (6), 1221-3
PubMed 1950869

Sert MB, Kaern J, Trope C (1991)
The close follow-up of immunosuppressed renal recipient women through colposcopy, cervical biopsy and FCM DNA content analysis
Eur J Cancer, 27 (3), 302
PubMed 1827319

Tropé C, Kaern J, Pettersen EO, Iversen OE (1991)
[DNA examinations in gynecological cancer and breast cancer]
Tidsskr Nor Laegeforen, 111 (13), 1638-42
PubMed 2063365

Tropé C, Kaern J, Vergote I (1991)
Intraperitoneal antineoplastic agents in the management of ovarian cancer
Eur J Surg Suppl (561), 83-6
PubMed 1720054

Publications 1990

Kaern J, Tropé C, Abeler V, Iversen T, Kjørstad K (1990)
A phase II study of 5-fluorouracil/cisplatinum in recurrent cervical cancer
Acta Oncol, 29 (1), 25-8
PubMed 2310600

Kaern J, Trope C, Kjorstad KE, Abeler V, Pettersen EO (1990)
Cellular DNA content as a new prognostic tool in patients with borderline tumors of the ovary
Gynecol Oncol, 38 (3), 452-7
PubMed 2172121

Kaern J, Tropé C, Kjørstad KE, Nordal R, Sundfør K, Vergote I, Vossli S, Abeler V, Sandvei R (1990)
[A phase II study of 5-fluorouracil/cisplatin in recurrent cervical cancer]
Tidsskr Nor Laegeforen, 110 (21), 2759-62
PubMed 2219049

Tropé C, Kaern J, Vergote I, Vossli S (1990)
A phase II study of etoposide combined with ifosfamide as second-line therapy in cisplatin-resistant ovarian carcinomas
Cancer Chemother Pharmacol, 26 Suppl, S45-7
PubMed 2347051

Publications 1989

Trope C, Lindahl B, Kaern J, Iversen OE (1989)
Usefulness of flow cytometric DNA measurements in genital and breast cancers
Eur J Gynaecol Oncol, 10 (3), 191-5
PubMed 2659366

Tveit KM, Kaern J, Hoifodt HK, Pettersen EO, Abeler V, Davy M, Hannisdal E, Trope C (1989)
Colony-forming ability of human ovarian carcinomas in the Courtenay soft agar assay
Anticancer Res, 9 (6), 1577-82
PubMed 2483300

Publications 1988

Asmussen M, Kaern J, Kjoerstad K, Wright PB, Abeler V (1988)
Primary adenocarcinoma localized to the fallopian tubes: report on 33 cases
Gynecol Oncol, 30 (2), 183-6
PubMed 3371742

Publications 1985

Secher NJ, Kaern J, Hansen PK (1985)
Intrauterine growth in twin pregnancies: prediction of fetal growth retardation
Obstet Gynecol, 66 (1), 63-8
PubMed 3892389

Publications 1984

Mølgaard IL, Nielsen PB, Kaern J (1984)
A study of the incidence of neonatal conjunctivitis and of its bacterial causes including Chlamydia trachomatis. Clinical examination, culture and cytology of tear fluid
Acta Ophthalmol (Copenh), 62 (3), 461-71
PubMed 6380204

Publications 1983

Mølgaard IL, Nielsen PB, Kaern J (1983)
A study of inclusion conjunctivitis in newborn and young adults. Clinical picture, culture, conjunctival scrapings and cytology of the tear fluid in 12 cases
Acta Ophthalmol (Copenh), 61 (6), 969-84
PubMed 6362323